Company Directory - Petros Pharmaceuticals, Inc.
Company Details - Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc.
WebsitePetros Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapies. The company has garnered attention recently with a significant stock surge of 120%, reflecting investor interest in its progress within the competitive pharmaceutical landscape.
CCI Score
CCI Score: Petros Pharmaceuticals, Inc.
-16.13
0.01%
Latest Event
Petros Pharmaceuticals Partners with Big Data Provider to Enhance Rx-to-OTC Switch
Petros Pharmaceuticals, Inc. has announced a collaboration with a renowned Big Data analytics firm to integrate advanced document capture and identity verification technology into its Software-as-a-Medical Device (SaMD) platform. This partnership aims to streamline the Rx-to-OTC conversion process by ensuring that only appropriately authenticated patients access formerly prescription-only medications, adhering to FDA guidance while enhancing consumer safety.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ENABLER
Petros Pharmaceuticals, Inc. is currently rated as an Enabler.
Latest Events
- MAR202025
Petros Pharmaceuticals, Inc. has announced a collaboration with a renowned Big Data analytics firm to integrate advanced document capture and identity verification technology into its Software-as-a-Medical Device (SaMD) platform. This partnership aims to streamline the Rx-to-OTC conversion process by ensuring that only appropriately authenticated patients access formerly prescription-only medications, adhering to FDA guidance while enhancing consumer safety.
+60
Business Practices and Ethical Responsibility
March 26
Petros Pharmaceuticals is demonstrating responsible business practices by closely following FDA guidance and incorporating consumer safety measures in its Rx-to-OTC transition strategy. The adherence to regulatory standards and engagement in transparent, ethical innovation reflect positively on its business practices and ethical responsibility.
+60
Technology and Services Impact
March 26
By integrating advanced AI-driven identity verification and big data analytics into its technological platform, Petros Pharmaceuticals enhances the reliability and efficiency of its authentication processes. This investment in technology not only supports improved healthcare outcomes but also sets a standard for the responsible use of technology within the industry, despite the need for ongoing vigilance regarding data privacy.
- MAR112025
An analysis highlighting the pervasive issue of forced labor in global supply chains. The article warns that companies, including those in the pharmaceutical sector like Petros Pharmaceuticals, face significant ethical and reputational risks if they do not proactively ensure transparency and ethical sourcing practices. The lack of clear initiatives around supply chain oversight suggests potential vulnerability to indirect complicity in forced labor abuses.
-40
Supply Chain Ethics
March 26
The article underscores the systemic risk of forced labor within global supply chains, a key concern under the 'Supply Chain Ethics' category. Given that pharmaceutical companies like Petros Pharmaceuticals operate within complex global supply networks, a lack of proactive measures to ensure ethical sourcing and labor practices raises serious concerns. This negative rating reflects the potential for indirect complicity in forced labor abuses if adequate oversight is not implemented.
- JAN312025
An analysis of significant campaign contributions and lobbying expenditures by pharmaceutical companies, highlighting concerns about the industry's influence on U.S. politics and potential alignment with authoritarian practices.
-50
Political Contributions and Lobbying Efforts
March 26
The article details how pharmaceutical companies have funneled substantial financial contributions into political campaigns and engaged in intense lobbying efforts. This spending, aimed at influencing legislative processes, raises alarms about undue corporate influence over policymaking, potentially undermining democratic accountability and facilitating authoritarian practices. Such activities are viewed negatively from an anti-fascist perspective, contributing to a lower score.
Should we be concerned with politicians receiving pharma money ...
- JAN072025
Petros Pharmaceuticals has unveiled its proprietary SaaS platform, integrating quantum computing and AI to facilitate the Rx-to-OTC switch in compliance with newly approved FDA ACNU rules. This move underscores the company's commitment to ethical business practices and technological innovation that enhances consumer access to medication.
+60
Business Practices and Ethical Responsibility
March 26
Petros Pharmaceuticals demonstrates a robust adherence to regulatory guidelines by aligning its innovative platform with FDA’s ACNU rule for Rx-to-OTC switches. This reflects a commitment to ethical business practices and enhancing consumer access to medication, which is crucial in building trust and public accountability.
+60
Technology and Services Impact
March 26
The company’s strategic deployment of quantum computing and AI in its SaaS platform to assist pharmaceutical companies in achieving Rx-to-OTC switches represents a forward-thinking use of technology. This initiative not only drives innovation in the healthcare sector but also supports improved consumer access to drugs, emphasizing a positive technological impact.
- OCT152024
A report by C4ADS highlights forced labor risks in the pharmaceutical supply chain, particularly linked to production in China’s Xinjiang Uyghur Autonomous Region. Although Petros Pharmaceuticals is not explicitly named, its inclusion in the global pharmaceutical industry raises concerns that it could be indirectly implicated if supply chain due diligence is not rigorously enforced.
-90
Supply Chain Ethics
March 26
C4ADS' report exposes a troubling connection between forced labor practices in Xinjiang and the pharmaceutical supply chain. While the report does not directly implicate Petros Pharmaceuticals, the risk associated with insufficient supply chain oversight in the pharmaceutical industry raises serious ethical concerns. Such practices undermine human rights and ethical responsibility, potentially linking companies to forced labor scenarios. The negative score reflects the high risk and urgency for companies to audit and reform their supply chain practices.
- MAR202023
Data from OpenSecrets indicates that pharmaceutical companies, including Petros Pharmaceuticals, are implicated in substantial political contributions and lobbying efforts. Such activities can enable these firms to shape policies in favor of authoritarian interests, potentially undermining democratic processes.
-50
Political Contributions and Lobbying Efforts
March 26
OpenSecrets data reveals that the pharmaceutical sector has been heavily involved in political contributions and lobbying activities. This involvement is concerning from a public and political behavior standpoint because such contributions can enable influence over regulatory and political processes in ways that support authoritarian policies. Although the article does not mention Petros Pharmaceuticals explicitly, its membership in the industry makes it susceptible to these practices, warranting a significant negative rating.
Alternatives
Bagsværd, Denmark
18.81
Paris, France
0.42
New Brunswick, United States
0.00
Corporation
0.00
Corporation
-12.69
Corporation
-18.02
Brentford, United Kingdom
18.03
Laval, Canada
15.65
Nanaimo, Canada
2.14
Tokyo, Japan
-7.42
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 424210
- Drugs and Druggists' Sundries Merchant Wholesalers
- 446110
- Pharmacies and Drug Stores